Genprex Inc. (NASDAQ: GNPX) announced that research collaborators presented preclinical data on the company's diabetes gene therapy at the 2026 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE